

2024-2025 ExCom ELECTIONS NOMINEE BIOSKETCH FORM

NAME	Tomasz Burzykowski
PRESENT POSITION	Professor, Data Science Institute of Hasselt University, Belgium Vice-President of Research, IDDI, Belgium Visiting Professor, Dept. of Biostatistics and Medical Informatics, Medical University of Bialystok, Poland
DEGREES	MSc in Applications of Mathematics (Warsaw University, Poland) MSc in Biostatistics (Hasselt University, Belgium) PhD in Mathematics (Hasselt University, Belgium)
MAIN RESEARCH INTERESTS	clinical trials, survival analysis, mixed-effects models, surrogates, omics
SELECTED PUBLICATIONS IN CLINICAL BIOSTATISTICS (LIMIT TO 5)	Garcia Barrado L, <u>Burzykowski</u> T (2021) Bayesian biomarker-driven outcome- adaptive randomization with an imperfect biomarker-assay. <i>Clinical Trials</i> , 18, 137-146 (DOI: 10.1177/1740774520964202).
	Burzykowski T (2022) Semi-parametric accelerated failure-time model: a useful alternative to the proportional-hazards model in cancer clinical trials. <i>Pharmaceutical Statistics</i> , 21, 292-308 (DOI: 10.1002/pst.2169).
	Deltuvaite-Thomas V, <u>Burzykowski</u> T (2023) Operational characteristics of univariate generalized pairwise comparisons with missing data. <i>Communications in Statistics - Simulation and Computation</i> (DOI: 10.1080/03610918.2023.2253380).
	Coart E, Bamps P, Quinaux E, Sturbois G, Saad E, <u>Burzykowski</u> T, Buyse M (2023) Minimization in randomized clinical trials. <i>Statistics in Medicine</i> , 42, 5285-5311 (DOI: 10.1002/sim.9916).
	Garcia Barrado L, <u>Burzykowski</u> T (2024) Using an early outcome as a sole source of information of interim decisions regarding treatment effect on a long-term endpoint: the non-Gaussian case. <i>Pharmaceutical Statistics</i> , 23(6), 928-938 (DOI: 10.1002/pst.2398).
PAST AND CURRENT PARTICIPATION IN ISCB ACTIVITIES	Executive Committee member (2011-2015; 2017-2025) Vice-President (2021-2022) President (2023-2024) Past-President (2024-2025)
GOALS AND VISION FOR THE ISCB	 ISCB should continue supporting biostatisticians across the globe, and especially in regions where educational offer for biostatistics is scarce and biostatistical community is weak. To help those interested in getting biostatistical education, the Society should be extending the educational offer. ISCB should become THE reference point when it comes to biostatistics-related questions.